Le Lézard
Classified in: Health
Subject: NPT

AMCP Foundation 7th Annual Research Symposium Examines Benefits of Value-Based Health Care From Multiple Stakeholder Perspectives


GRAPEVINE, Texas, Oct. 18, 2017 /PRNewswire-USNewswire/ -- The perception of what is "valuable" in any particular therapy can vary widely between providers, patients and payers, according to panelists at the Academy of Managed Care Pharmacy (AMCP) Foundation's 7th Annual Research Symposium.

www.amcp.org/amcp-foundation

More than 170 health care thought leaders from across the country gathered for the half-day event on "Value-Based Health Care: Identifying Benefits for Patients, Providers and Payers." The diverse experts shared their views on identifying and utilizing value to improve care.

"Those of us involved in value formulations need to recognize that our perspective is not the only perspective, that decisions are made by a variety of stakeholders and gatekeepers, and they all have their own inherent value equations," said symposium moderator Clifford Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research at The Lewin Group. "If I'm ignoring those perspectives, then my value calculus is going to be suboptimal."

The symposium was held Oct. 16 as a preconference to the AMCP Nexus 2017 conference, held Oct. 17-19 at the Gaylord Texan Hotel and Convention Center, Grapevine, Texas.

"Value in health care is a vital topic, and our presenters shared various perspectives of this concept beyond costs," says Paula J. Eichenbrenner, CAE, Executive Director, AMCP Foundation. "The patient perspective is of particular importance in the value debate. Indeed, recognizing and integrating patient perspectives into value assessments should enable pharmaceutical manufacturers, providers, health plans and payers to develop and deliver products and services with a higher value to society."

Delivering the keynote address was well-known patient advocate Alan Balch, PhD, CEO of the Patient Advocate Foundation. His talk included discussions on creating a holistic approach to patient care; determining patient priorities and their value; and building understanding and acceptance of patient values with payers and policy-makers. The agenda also featured panel discussions on topics such as patient engagement, consumer priorities and the provider and payer perspectives on value-based care

The symposium included presentation of an AMCP Foundation Best Poster Award for the most highly rated research abstract in value-based health care. Ten individuals also received scholarships to attend the Symposium, thanks to the support from Amgen, Inc., Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., National Pharmaceutical Council, Pfizer, Inc., and QuintilesIMS. For more information, visit www.amcp.org/2017Fdn_Symp/.

About AMCP Foundation
Established in 1990, the 501(c)3 nonprofit AMCP Foundation exists to advance collective knowledge and insights on major issues associated with the practice of pharmacy in managed health care settings. By facilitating innovative research initiatives and providing educational opportunities to learn about managed care pharmacy, the AMCP Foundation invests in the future of managed care. The Foundation is the philanthropic arm of the Academy of Managed Care Pharmacy. www.amcp.org/amcp-foundation/

 

SOURCE Academy of Managed Care Pharmacy Foundation


These press releases may also interest you

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...

at 00:16
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...



News published on and distributed by: